Quality of independent review board/ethics committee oversight in clinical trials in India
2011

Quality of Ethics Committee Oversight in Clinical Trials in India

Editorial Evidence: low

Author Information

Author(s): Pandiya Anvita

Primary Institution: Eli Lilly and Company (India) Pvt. Ltd.

Conclusion

Ethics Committees in India face significant challenges that hinder their ability to effectively oversee clinical trials.

Supporting Evidence

  • Ethics Committees often lack adequate training and resources.
  • Many ECs do not have standard operating procedures or proper record keeping.
  • Senior medical professionals dominate ECs, limiting input from non-scientific members.

Takeaway

Ethics Committees help keep patients safe in clinical trials, but they need more training and resources to do their job well.

Methodology

The article discusses the functioning and challenges faced by Ethics Committees in India based on surveys and studies.

Potential Biases

Potential for bias exists due to conflicts of interest and lack of diverse representation in Ethics Committees.

Limitations

The article does not provide specific data or quantitative analysis of the issues discussed.

Participant Demographics

EC members are generally senior, highly educated, and experienced in research, but lack representation from non-scientific backgrounds.

Digital Object Identifier (DOI)

10.4103/2229-3485.80364

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication